Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27439147 | 0.96 | LTA4H (0.58) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL27439146 | 0.96 | LTA4H (0.58) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL1859995 | 0.93 | LTA4H (0.52) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL6716210 | 0.90 | FFAR1 (0.61) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL22367637 | 0.89 | MMP2 (0.63) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL29779565 | 0.89 | MMP2 (0.63) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL1856424 | 0.88 | GPR132 (0.54) | LTA4HEPHX2MMP12MMP2MMP3 | |
| SCHEMBL28860722 | 0.87 | FFAR1 (0.64) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL28224291 | 0.87 | FFAR1 (0.64) | LTA4HEPHX2FFAR1FFAR4MMP12 | |
| SCHEMBL1865673 | 0.87 | LTA4H (0.55) | LTA4HEPHX2FFAR1FFAR4MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | claimed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | LTA4H 2258/4885EPHX2 1919/4885FFAR1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.